Nova Eye Medical (EYE) Discussion, page-2358

Agreed, I think many people are used to seeing endless cap raises for pre revenue companies, where the funds appear to be solely used to fund the large salaries of management whilst they slowly progress with getting to market, and that has created this whole negative perception around raising capital.

EYE is completely different. It already has its product in the market. These funds are not being used simply to keep the company alive until the next capital raise, but rather, to deliver even stronger growth than they're already recording and near term positive cash flow. This will almost certainly be very accretive for shareholders, and is the result of the company identifying further growth opportunities. They're not burning through cash, they're clearly investing in growth. That's quite evident from the spectacular growth they managed to record in the USA, despite the negative weight of the LCD.